Immunotherapy against antigenic tumors: A game with a lot of players

Cellular and Molecular Life Sciences

Volumn 59, Issue 2, 2002, Pages 230-240

  Perez Diez A ^a,b   Marincola, F M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antigenic tumors; Cancer vaccines; Immune response; Microarrays; Tumor microenvironment

Indexed keywords

CANCER VACCINE;

CANCER IMMUNOLOGY; CANCER PATIENT; CANCER SUSCEPTIBILITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; REVIEW; TUMOR REJECTION;

ANTIGENS, CD8; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; EPITOPES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MODELS, IMMUNOLOGICAL; NEOPLASMS; TUMOR ESCAPE; VIRAL VACCINES;

EID: 0036183146     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-002-8419-5     Document Type: Review

References (64)

1. Human tumor antigens: Implications for cancer vaccine development
2. Tolerance reconsidered: A critical survey
3. Localization dose and time of antigens determine immune reactivity
4. Innate immune recognition and control of adaptive immune responses
5. An innate sense of danger
6. Danger signal: SOS to the immune system
7. Progress in human tumour immunology and immunotherapy
8. Cancer vaccines
9. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance
10. Tumor antigens
11. Specific carcinoembryonic antigens of the human digestive system
12. Cellular and humoral immunity to different types of human neoplasms
13. Cytotoxicity of human rosette-forming blood lymphocytes on cultivated human tumor cells
14. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas
15. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
16. T-cell clones from melanoma patients immunized against an anchor modified gp 100 peptide display discordant effector phenotypes
17. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity
18. Localization of 11 lindium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: Augmentation with cyclophosphamide and correlation with response
19. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
20. How do cytotoxic lymphocytes kill their targets?
21. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
22. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 + cancers
23. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
24. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
25. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
26. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma
27. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
28. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution
29. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
30. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells
31. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells
32. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
33. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
34. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma associated antigens MART-1 and gp 100
35. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
36. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway
37. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
38. Recombinant Listeria monocytogenes cancer vaccines
39. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma
40. Tumor prevention with recombinant vaccinia
41. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1
42. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/MelanA gene
43. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
44. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
45. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy form metastatic melanoma
46. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
47. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer
48. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
49. A shift in the phenotype of MelanA-specific CTL identifies melanoma patients with an active tumor-specific immune response
50. Status of activation of circulating vaccine-elicited CD8+ T cells
51. Kinetics of TCR use in response to repeated epitope-specific immunization
52. Quantitative monitoring of gene expression patterns with a complementary DNA microarray
53. High fidelity mRNA amplification for gene profiling using cDNA microarrays
54. A natural history of melanoma: Serial gene expression analysis
55. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice
56. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma
57. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulated potent, specific and long-lasting anti-tumor immunity
58. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
59. Eradication of established tumors by CD8+ T cell adoptive immuntherapy
60. Genes expressed in human tumor endothelium
61. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3
62. Human monocyte chemotactic protein-3 (MCP-3) molecular cloning of the cDNA and comparison with other chemokines
63. Monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes
64. Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase: Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle